The Use of Real-World Data to Optimize Oncology Drug Development and Access
Amsterdam, Netherlands – 21 & 22 November 2019
Due to the current interest in Real World Data both from Industry but especially the EMA and FDA, the Cancer Drug Development Forum organizes the 2nd CDDF multi-stakeholder workshop on the Use of Real-World Data to Optimize Oncology Drug Development and Access on 21-22 November 2019 in Amsterdam, Netherlands.
The aim of the workshop is to have a multi-stakeholder discussion representing regulators, clinicians, HTA / payers, and policy makers on the challenges of developing RWD proposals in Oncology and share current experience on the best sources of RWD of high quality in Oncology Drug Development. We will discuss ways to enhance knowledge on benefit/risk as well as development and access to optimal treatment regimens.
The second edition will focus particularly on issues concerning methodology of collecting good quality and relevant information, and the specific requirement of Regulators to maximise the use of RWD in licensing decisions. We will also explore possible solutions to the current challenges and carry out collaborative search for agreements.
The target is a multidisciplinary audience of Patient Associations, Academia Representatives, EU and US Regulatory Bodies (EMA, FDA, National Agencies), Pharmaceutical Industry, and HTAs.
- John Smyth (University of Edinburgh – CDDF Board)
- Nafsika Kronidou Horst (Roche)
- Stefan Schwoch (Lilly)
- Eva Skovlund (Norwegian University of Science and Technology, NTNU)
- Discover the final programme
View the speakers’ presentation: slides
Read the executive summary of the RWD meeting
A full meeting summary will be available soon.